

Alternative Facts:

**Adherence to an Electronic Monitoring Device
(Wisepill) Does Not Always Reflect
Adherence to Medication**

**Nadia Nguyen, Reuben Robbins, Claude Ann Mellins,
Michelle Henry, Hetta Gouse, Cheng-Shiun Leu,
Andrea Norcini Pala, Patricia Warne, John Joska,
Robert H. Remien**

**HIV Center for Clinical and Behavioral Studies,
New York State Psychiatric Institute and Columbia University;
University of Cape Town**



Introduction

- Antiretroviral therapy (ART) non-adherence is a critical public health issue
 - ▶ More people on ART earlier in their disease course
 - ▶ Keeping patients engaged in care remains a challenge
- Efforts to study and improve ART adherence hampered by lack of objective measures of medication adherence
 - ▶ Annual viral loads may miss critical points for intervention
 - ▶ Need to target the right interventions to the right people at the right time

Objective Measures of Adherence

- Desirable traits of an objective adherence measure
 - ▶ Not subject to recall or social desirability bias
 - ▶ Minimal burden
 - ▶ Timely feedback
 - ▶ Measures medication ingestion
 - ▶ **Reflects biological outcomes**

Monitoring Adherence

Electronic monitoring devices (EMDs), such as Wisepill can provide objective, real-time measurement of adherence
... *but only if people use them as directed*



Wisepill device™

- Electronic pill box, holds 1 month pills
- Device openings recorded in real-time
- Data stored on device when service not available
- Batteries last up to 6 months; SMS reminders to charge batteries

KEY ASSUMPTION

Adherence to Wisepill device = Drug ingestion

But is this always true?

Does Wisepill use reflect viral load?

And is it true for everyone?

Does Wisepill use vary across participants?

Monitoring Adherence in Masivukeni



- Randomized controlled trial of a laptop based, lay-counselor delivered adherence intervention for ART initiators in Cape Town, South Africa
 - ▶ 432 HIV+ adults (mean age 33, 74% female)
 - ▶ Continuous Wisepill data for 12 months
 - ▶ Viral load from clinic records at ~4 months and ~12 months post ART initiation
 - ▶ Among participants with 12 month viral load data, >90% were virally suppressed

Data Analysis: Variable Definition

Viral Suppression: ≤ 40 copies/mL at 4 and 12 months

Wisepill Adherent: $\geq 80\%$ of prescribed device openings for a given month

$$\% \text{ Wisepill Adherence (openings)} = \frac{\# \text{ days device opened}}{\# \text{ days device detected as active}^*}$$

**usually 28 days - removed days device was not active (battery dead)*


Analysis sample : 203 virally suppressed participants

Data Analysis

- Group-based trajectory modeling to examine patterns of Wisepill use among participants who were virally suppressed at both 4 and 12 months post ART initiation
 - ▶ Latent variable model similar to latent class analysis (LCA)
 - ▶ Identify clusters (i.e. trajectory groups) of participants with similar patterns of Wisepill adherence over time
 - ▶ Considered models with 2-6 groups
 - ▶ To select best fitting model: Bayesian Information Criterion (BIC), group size, and average posterior probabilities
 - ▶ Proc Traj in SAS

Results: Wisepill Adherence


Overall trajectory of Wisepill use



Proportion of study participants who were Wisepill adherent (open device daily) $\geq 80\%$ of the time or more, by month on study

Results: Wisepill Adherence

Sub-group trajectories of Wisepill use



Great variation in Wisepill use among virally suppressed participants

Conclusions

ART-initiators enrolled in an randomized controlled trial in Cape Town, South Africa

- Overall, only 40% of virally suppressed participants were Wisepill adherent at 12 months
- Wisepill use patterns were not uniform across participants
 - ▶ Only 38% had a sustained high probability of being Wisepill adherent
 - ▶ But all participants in this analysis were virally suppressed

Conclusions

- Adherence measured by EMDs may not always reflect medication ingestion
 - ▶ Potential to underestimate ART adherence because of non-adherence to the device
 - ▶ **Caveat:** Great variation in how studies use Wisepill
 - ▶ From passive monitoring to active intervention
 - ▶ Influence participant adherence to device, medication, or both

Conclusions

- Importance of distinguishing between device adherence versus medication adherence/ingestion
- Need for biological measures of adherence beyond viral load that capture drug ingestion
 - ▶ Drugs levels in dried blood spots and hair samples
 - ▶ Ingestible sensors
- Consider the context
 - ▶ Study setting, study population, study design

Acknowledgements

HIV Center, NYSPI and Columbia University

Robert H. Remien, Ph.D.

Reuben Robbins, Ph.D.

Claude Ann Mellins, Ph.D.

Patricia Warne, Ph.D.

Javier López-Rios, B.A.

Cheng-Shiun Leu, Ph.D.

Bruce Levin, Ph.D.

University of Cape Town

John Joska, M.B.Ch.B.

Hetta Gouse, Ph.D.

Michelle Henry

Yoliswa Mtigeni

National Institute of Mental Health

**“Masivukeni: A Multimedia ART Adherence Intervention for
Resource-Limited Settings**

(R01-MH95576; PI: Robert H. Remien, Ph.D.)

NIMH Program Officer: Michael Stirratt, Ph.D.

HIV Center for Clinical and Behavioral Studies

(P30-MH43520; Center Director and PI: Robert H. Remien, Ph.D.)



HIV CENTER for Clinical and Behavioral Studies
at the New York State Psychiatric Institute and Columbia University